These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 28464741)

  • 21. [Clinical experience with radioiodine treatment of differentiated thyroid carcinoma].
    Ikekubo K; Saiki Y; Jeong S; Yamaguchi H; Ito H; Hino M; Ishihara T; Waseda N; Mori T
    Kaku Igaku; 1986 Nov; 23(11):1625-32. PubMed ID: 3820853
    [No Abstract]   [Full Text] [Related]  

  • 22. Contemporary surgical management of non-medullary thyroid malignancy.
    Odell MJ
    Mo Med; 2008; 105(3):250-6. PubMed ID: 18630306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effectiveness of high-dosage radioiodine therapy in the elimination of remnant tissue following total thyroidectomy].
    Schümichen C; Bulczak-Schmidt M; Blattmann H; Pauli-Harnasch C
    Nuklearmedizin; 1984 Oct; 23(5):265-9. PubMed ID: 6522276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Radioiodine therapy and radioiodine after-care in differentiated thyroid gland carcinomas].
    Börner AR; Müller-Gärtner HW
    Zentralbl Chir; 1997; 122(4):274-85. PubMed ID: 9221638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The use of 131I in the combined modality therapy of highly differentiated cancer of the thyroid gland].
    Baranauskas ZL; Mamontov VV; Valutskas KK
    Med Radiol (Mosk); 1989 Oct; 34(10):31-4. PubMed ID: 2811625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radioiodine-131 therapy for well-differentiated thyroid cancer--a quantitative radiation dosimetric approach: outcome and validation in 85 patients.
    Maxon HR; Englaro EE; Thomas SR; Hertzberg VS; Hinnefeld JD; Chen LS; Smith H; Cummings D; Aden MD
    J Nucl Med; 1992 Jun; 33(6):1132-6. PubMed ID: 1597728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patterns of relapse following radiotherapy for differentiated thyroid cancer: implication for target volume delineation.
    Azrif M; Slevin NJ; Sykes AJ; Swindell R; Yap BK
    Radiother Oncol; 2008 Oct; 89(1):105-13. PubMed ID: 18579244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Radiotherapy for Thyroid Cancer].
    Jingu K; Maruoka S; Umezawa R; Takahashi N
    Gan To Kagaku Ryoho; 2015 Jun; 42(6):666-9. PubMed ID: 26199238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Experience with a high-dose therapy concept in metastatic differentiated thyroid cancer].
    Grünwald F; Ruhlmann J; Ammari B; Knopp R; Hotze A; Biersack HJ
    Nuklearmedizin; 1988 Dec; 27(6):266-71. PubMed ID: 3217257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Presentation and practical management to optimize radioiodine treatment of well differentiated thyroid cancer: ablation of thyroid remnants with radioiodine.
    Janisch A; Altenbrunn HJ; Markwardt J
    Radiobiol Radiother (Berl); 1987; 28(5):707-10. PubMed ID: 3441634
    [No Abstract]   [Full Text] [Related]  

  • 31. Radioiodine therapy in differentiated thyroid cancer: a nuclear medicine perspective.
    Clarke SE
    Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):430-7. PubMed ID: 20537878
    [No Abstract]   [Full Text] [Related]  

  • 32. Efficacy of low-dose iodine-131 ablation of post-operative thyroid remnants: a study of 69 cases.
    Leung SF; Law MW; Ho SK
    Br J Radiol; 1992 Oct; 65(778):905-9. PubMed ID: 1422665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 131I dosimetry and thyroid stunning.
    Gerard SK; Park HM
    J Nucl Med; 2003 Dec; 44(12):2039-40; author reply 2040. PubMed ID: 14660731
    [No Abstract]   [Full Text] [Related]  

  • 34. Acute promyelocytic leukaemia following radioiodine therapy.
    Richards EM; Marcus RE
    Clin Lab Haematol; 1993; 15(1):55-8. PubMed ID: 8472497
    [No Abstract]   [Full Text] [Related]  

  • 35. Second Radioiodine Treatment: Limited Benefit for Differentiated Thyroid Cancer With Locoregional Persistent Disease.
    Hirsch D; Gorshtein A; Robenshtok E; Masri-Iraqi H; Akirov A; Duskin Bitan H; Shimon I; Benbassat C
    J Clin Endocrinol Metab; 2018 Feb; 103(2):469-476. PubMed ID: 29126111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Non-surgical treatment of thyroid neoplasms].
    Klepp O
    Tidsskr Nor Laegeforen; 1975 Aug; 95(23):1287-90. PubMed ID: 1179338
    [No Abstract]   [Full Text] [Related]  

  • 37. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
    Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
    Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complications, sequela and dosimetry of iodine-131 therapy for thyroid carcinoma.
    Bushnell DL; Boles MA; Kaufman GE; Wadas MA; Barnes WE
    J Nucl Med; 1992 Dec; 33(12):2214-21. PubMed ID: 1460519
    [No Abstract]   [Full Text] [Related]  

  • 39. Radioiodine-resistant differentiated thyroid cancer: hope for the future.
    Hodak SP; Carty SE
    Oncology (Williston Park); 2009 Aug; 23(9):775-6. PubMed ID: 19777763
    [No Abstract]   [Full Text] [Related]  

  • 40. Radioiodine therapy in patients with stage I differentiated thyroid cancer.
    Jonklaas J; Cooper DS; Ain KB; Bigos T; Brierley JD; Haugen BR; Ladenson PW; Magner J; Ross DS; Skarulis MC; Steward DL; Maxon HR; Sherman SI;
    Thyroid; 2010 Dec; 20(12):1423-4. PubMed ID: 21054207
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.